Facilitators and barriers to adolescent participation in a TB clinical trial.

The inclusion of adolescents in TB drug trials is essential for the development of safe, child-friendly regimens for the prevention and treatment of TB. TB Trials Consortium Study 31/AIDS Clinical Trials Group A5349 (S31/A5349) enrolled adolescents as young as 12 years old. We assessed investigator and coordinator described facilitators and barriers to adolescent recruitment, enrollment, and retention.Interviews were conducted with six investigators from sites that enrolled adolescent participants and six investigators from non-enrolling sites. Additionally, two focus groups were conducted with study coordinators from enrolling sites and two focus groups with non-enrolling sites. Discussions were transcribed, analyzed, summarized, and summaries were reviewed by Community Research Advisors Group members and research group representatives for content validity.Investigators and coordinators attributed the successful enrollment of adolescents to the establishment and cultivation of external partnerships, flexibility to accommodate adolescents' schedules, staff engagement, recruitment from multiple locations, dedicated recruitment staff working onsite to access potential participants, creation of youth-friendly environments, and effective communications. Non-enrolling sites were mainly hindered by regulations. Suggestions for improvement in future trials focused on study planning and site preparations.Proactive partnerships and collaboration with institutions serving adolescents helped identify and reduce barriers to their inclusion in this trial..

[Comparison of techniques used to screen blood donations for malaria antibodies]. / Comparaison de techniques de dépistage des anticorps antipaludiques utilisées en transfusion.

In France all but one of the serological tests used to screen blood donations rely on ELISA-based techniques. The exception is malaria antibody detection that is performed by the indirect fluorescent antibody technique using commercially available kits. The reagent kit used at the French Army Blood Bank (FABB) is Falciparum-Spot IF (bioMerieux). However since the antigens in this kit are obtained from group A1 red blood cell cultures, false positive results can occur due to binding of natural antiglobulins. Over a 10-month period at the FABB, we disqualified a total of 55 donations (5.02% of total donations) because of positive Falciparum-Spot IF@1000 test results. Most disqualified donations (84%) involved donations with group O red blood cells. In the present retrospective study, these 55 disqualified donations were used to compare the specificity of three other serological tests used for detection of malaria antibodies: Falciparum-SpotIF after elimination of natural antiglobulins by absorption and neutralization with Witebski reagent and Paludix (Diagast). Use of all three techniques provided a specificity gain of over 87% but elimination using Witebski reagent led to a loss of sensitivity. At the FABB we have been using the Falciparum-Spot IF kit after elimination of natural antiglobulins since April 2001. Only 1.62% of donations tested have been disqualified due to the presence of malaria antibodies including 52% with group O red blood cells.